(+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats

Obesity Research

Volumn 13, Issue 11, 2005, Pages 1915-1924

  Banz, William J ^a,b   Davis, Jeremy ^a,b   Steinle, Jena J ^b   Adler, Stuart ^b   Oitker, Jennifer ^b   Winters, Todd A ^a,b   Higginbotham, D Allan ^a,b   Hou, Yuqing ^a   Henry, Nancy ^a   Peterson, Richard ^c   Meyers, Cal Y ^a  

^a SOUTHERN ILLINOIS UNIVERSITY   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Insulin resistance; Peroxisome proliferator activated receptor; Selective estrogen receptor modulators; Zucker diabetic fatty rat

Indexed keywords

ANIMALIA; RODENTIA;

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BISDEHYDRODOISYNOLIC ACID; CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENANTHRENE DERIVATIVE; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CHEMISTRY; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; KIDNEY; LIVER; METABOLIC SYNDROME X; OBESITY; ORGAN SIZE; PATHOLOGY; RANDOMIZATION; RAT; RISK FACTOR; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; KIDNEY; LIVER; METABOLIC SYNDROME X; OBESITY; ORGAN SIZE; PHENANTHRENES; PPAR ALPHA; PPAR GAMMA; RANDOM ALLOCATION; RATS; RATS, ZUCKER; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 33644818968     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2005.236     Document Type: Article

References (33)

1. Terenius L. Inhibition of 17-beta-oestradiol uptake in mouse uterus by doisynolic and allenoic acid derivatives: an in vitro differentiation between true oestrogens and pro-oestrogens. Acta PharmacolToxicol. 1967;25:313-22.
2. Meyers CY, Hou Y, Winters TA, Banz WJ, Adler S. Activities of a non-classical estrogen, Z-bis-dehydrodoisynolic acid, with ERalpha and ERbeta. J Steroid Biochem Mol Biol. 2002;82:33-44.
3. Meyers CY, Hou Y, Robinson PD, Adler S, Banz WJ, Winters TA. Absolute structure determination of the highly biologically active bisdehydrodoisynolic acids. J Pharm Sci. 2000;89:513-8.
4. Meyers CY, Lutfl HG, Adler S. Transcriptional regulation of estrogen-responsive genes by non-steroidal estrogens: doisynolic and allenolic acids. J Steroid Biochem Mol Biol. 1997;62:477-89.
5. Meyers CY, Kolb VM, Gass GH, Rao BR, Roos CF, Dandliker WB. Doisynolic-type acids: uterotropically potent estrogens which compete poorly with estradiol for cytosolic estradiol receptors. J Steroid Biochem. 1988;31:393-404.
6. Meyers CY. Doisynolic acid type compounds as weight and appetite suppressing and control agents. Patent 5420161. 1995.
7. Wilson T, March H, Banz WJ, et al. Antioxidant effects of phyto-and synthetic-estrogens on cupric ion-induced oxidation of human low-density lipoproteins in vitro. Life Sci. 2002;70:2287-97.
8. Banz WJ, Winters TA, Hou Y, Adler S, Meyers CY. Comparative effects of the selective estrogen receptor modulators (-)-, ( + )- and (+/-)-Z bisdehydrodoisynolic acids on metabolic and reproductive parameters in male and female rats. Horm Metab Res. 1998;30:730-6.
9. Djouadi F, Weinheimer CJ, Saffitz JE, et al. A genderrelated detect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha- deficient mice. J Clin Invest. 1998;102:1083-91.
10. Mezel O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 2003;133:1238-43.
11. Mayer DF. Raloxifene and risk of cardiovascular events. JAMA. 2002;288:42-3.
12. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab. 2001;86:2763-8.
13. Finkelstein JA. Long-term effects of diethylstilbestrol (DES) on genetically obese and non-obese female Zucker rats. Brain Res Bull. 1986;17:885-8.
14. Gale SK, Van Itallie TB. Genetic obestiy: estrogenic influences on the body weight and food intake of lean and obese adult Zucker (fa/fa) rats. Physiol Behav. 1979;23:111-20.
15. Gray JM, Greenwood MR. Effect of estrogen on lipoprotein lipase activity and cytoplasmic progestin binding sites in lean and obese Zucker rats. Proc Soc Exp Biol Med. 1984;175: 374-9.
16. Stevenson FT, Wheeldon CM, Gades MD, Kaysen GA, Stern JS, van Goor H. Estrogen worsens incipient hypertriglyceridemic glomerular injury in the obese Zucker rat. Kidney Int. 2000;57:1927-35.
17. Wilson JN, Wilson SP, Eaton RP. Influence of genetic hyperlipemia in the Zucker rat upon the lipemic response to graded estradiol exposure. Atherosclerosis. 1982;41:99-114.
18. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta. 2002;1585:202-12.
19. Cheng AY, Fantus IG. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother. 2004;38:817-20.
20. Meyers CY, Banz WJ, Adler SR, Winters TA, Hou Y, Dandliker WB. Method for treating or preventing prostatic conditions. Patent 6,608,111. 2003.
21. Henry N, Hou Y, Roeder M, et al. Effects of (+)-Z-bisdehydrodoisynolic acid on the rat prostate. Biol Reprod. 2001;64:227 (abstr).
22. Reeves PG, Nielsen FH, Fahey GC, Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-51.
23. Meyers CY, Kolb VM, Dandliker WB. Doisynolic acids: potent estrogens with very low affinity for estrogen receptors. Res Commun Chem Pathol Pharmacol. 1982;35:165-8.
24. Harris RB, Martin RJ. Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol. 1984;247:R380-6.
25. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML. Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res. 1986;58:38-46.
26. Cimini CM, Weiss HR. Microvascular morphometry and perfusion in renal hypertension-induced cardiac hypertrophy. Am J Physiol. 1988;255:H 1384-90.
27. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP. Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. J Biol Chem. 2000;275:16302-8.
28. Wang X, Kilgore MW. Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma I in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol. 2002;194:123-33.
29. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol. 1995;9:794-804.
30. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med. 2001;7:395-400.
31. Crawford SE, Qi C, Misra P, Stellmach V, Rao MS, Engel JD, Zhu Y, Reddy JK. Defects in heart, eye, and megakaryocytes in peroxisome proliferator activator receptor binding protein (PBP) null embryos implicate GATA family of transcription factors. J Biol Chem, 2002;277:3585-92.
32. Sassa Y, Hata Y, Aiello LP, Taniguchi Y, Kohno K, Ishibashi T. Bifunctional properties of peroxisome proliferatoractivated receptor gamma1 in KDR gene regulation mediated viii interaction with both Spl and Sp3. Diabetes. 2004;53: 1222-9.
33. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A. Ligands of peroxisome proliferator-activated receptor gamma increase the generation of vascular endothelial cell growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol. 2000;47:1147-57.